Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.49 |
| ▸ | HTR1A | P08908 | 5/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 5/20 | 0.48 |
| ▸ | HTR6 | P50406 | 5/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037273 | 1.00 | POLB (0.61) | POLBHRH4HTR1ADRD2HTR2A | |
| SCHEMBL2037270 | 1.00 | POLB (0.61) | POLBHRH4HTR1ADRD2HTR2A | |
| SCHEMBL2037138 | 0.89 | POLB (0.61) | POLBHRH4HTR1ADRD2HTR2A | |
| SCHEMBL2037137 | 0.89 | POLB (0.61) | POLBHRH4HTR1ADRD2HTR2A | |
| SCHEMBL2031705 | 0.87 | POLB (0.65) | POLBHRH4HTR1ADRD2HTR2A | |
| SCHEMBL2031702 | 0.87 | POLB (0.65) | POLBHRH4HTR1ADRD2HTR2A | |
| SCHEMBL13278124 | 0.84 | POLB (0.77) | POLBHRH4HTR1ADRD2HTR2A | |
| SCHEMBL13278125 | 0.84 | POLB (0.77) | POLBHRH4HTR1ADRD2HTR2A | |
| SCHEMBL2035524 | 0.81 | POLB (0.58) | POLBHRH4HTR1ADRD2HTR2A | |
| SCHEMBL2035522 | 0.81 | POLB (0.58) | POLBHRH4HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516397-B1 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME (NL) | 2016-07-13 | — | — | EP | claimed |
| US-8952001-B2 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | claimed |
| EP-2516397-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | MSD Oss B.V. (NL) | 2012-10-31 | — | — | EP | claimed |
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-10-18 | — | — | US | claimed |
| WO-2011076723-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | N.V. ORGANON (NL) | 2011-06-30 | — | — | WO | claimed |
| EP-2516397-B1 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME (NL) | 2016-07-13 | — | — | EP | disclosed |
| US-8952001-B2 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2516397-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | MSD Oss B.V. (NL) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076723-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | N.V. ORGANON (NL) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | HCN1, HCN3, HCN2 | POLB 3931/4885HRH4 54/4885HTR1A 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.